Anti-tumour effect of tocilizumab for osteosarcoma cell lines.,Bone & Joint Research

当前位置： X-MOL 学术 › Bone Joint Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Anti-tumour effect of tocilizumab for osteosarcoma cell lines.
Bone & Joint Research ( IF 4.7 ) Pub Date : 2020-11-13 , DOI: 10.1302/2046-3758.911.bjr-2020-0123.r1
Tomohito Hagi ₁ , Tomoki Nakamura ₁ , Kouji Kita ₁ , Takahiro Iino ₁ , Kunihiro Asanuma ₁ , Akihiro Sudo ₁

Affiliation

Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines.

中文翻译：